These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 23680146)
1. RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Holderfield M; Merritt H; Chan J; Wallroth M; Tandeske L; Zhai H; Tellew J; Hardy S; Hekmat-Nejad M; Stuart DD; McCormick F; Nagel TE Cancer Cell; 2013 May; 23(5):594-602. PubMed ID: 23680146 [TBL] [Abstract][Full Text] [Related]
2. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576 [TBL] [Abstract][Full Text] [Related]
3. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705 [TBL] [Abstract][Full Text] [Related]
4. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Karreth FA; DeNicola GM; Winter SP; Tuveson DA Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255 [TBL] [Abstract][Full Text] [Related]
5. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863 [TBL] [Abstract][Full Text] [Related]
6. Relief of inhibitory autophosphorylation activates RAF. Cancer Discov; 2013 Jul; 3(7):OF31. PubMed ID: 23847376 [TBL] [Abstract][Full Text] [Related]
7. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Friday BB; Yu C; Dy GK; Smith PD; Wang L; Thibodeau SN; Adjei AA Cancer Res; 2008 Aug; 68(15):6145-53. PubMed ID: 18676837 [TBL] [Abstract][Full Text] [Related]
8. Analyses of the oncogenic BRAF Cope NJ; Novak B; Liu Z; Cavallo M; Gunderwala AY; Connolly M; Wang Z J Biol Chem; 2020 Feb; 295(8):2407-2420. PubMed ID: 31929109 [TBL] [Abstract][Full Text] [Related]
9. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers. Rebocho AP; Marais R Oncogene; 2013 Jun; 32(26):3207-12. PubMed ID: 22926515 [TBL] [Abstract][Full Text] [Related]
10. Drug discovery: inhibitors that activate. Cichowski K; Jänne PA Nature; 2010 Mar; 464(7287):358-9. PubMed ID: 20237552 [No Abstract] [Full Text] [Related]
11. Raf: a strategic target for therapeutic development against cancer. Beeram M; Patnaik A; Rowinsky EK J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185 [TBL] [Abstract][Full Text] [Related]
12. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration. Mooz J; Oberoi-Khanuja TK; Harms GS; Wang W; Jaiswal BS; Seshagiri S; Tikkanen R; Rajalingam K Sci Signal; 2014 Aug; 7(337):ra73. PubMed ID: 25097033 [TBL] [Abstract][Full Text] [Related]
13. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant. Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890 [TBL] [Abstract][Full Text] [Related]
14. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Roberts PJ; Der CJ Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923 [TBL] [Abstract][Full Text] [Related]
16. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958 [TBL] [Abstract][Full Text] [Related]
17. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. Baitei EY; Zou M; Al-Mohanna F; Collison K; Alzahrani AS; Farid NR; Meyer B; Shi Y J Pathol; 2009 Apr; 217(5):707-15. PubMed ID: 19156774 [TBL] [Abstract][Full Text] [Related]
18. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules. Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246 [TBL] [Abstract][Full Text] [Related]
19. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Chen J; Shen Q; Labow M; Gaither LA Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556 [TBL] [Abstract][Full Text] [Related]
20. RAF inhibitors that evade paradoxical MAPK pathway activation. Zhang C; Spevak W; Zhang Y; Burton EA; Ma Y; Habets G; Zhang J; Lin J; Ewing T; Matusow B; Tsang G; Marimuthu A; Cho H; Wu G; Wang W; Fong D; Nguyen H; Shi S; Womack P; Nespi M; Shellooe R; Carias H; Powell B; Light E; Sanftner L; Walters J; Tsai J; West BL; Visor G; Rezaei H; Lin PS; Nolop K; Ibrahim PN; Hirth P; Bollag G Nature; 2015 Oct; 526(7574):583-6. PubMed ID: 26466569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]